{"id":83077,"date":"2020-10-08T00:00:00","date_gmt":"2022-11-09T14:26:38","guid":{"rendered":"https:\/\/mdbc1.wpengine.com\/?post_type=eb_course&#038;p=83077"},"modified":"2023-05-02T09:31:37","modified_gmt":"2023-05-02T13:31:37","slug":"maladie-renale-en-presence-de-diabete-de-type-2-optimiser-la-protection-renale-a-laide-des-inhibiteurs-du-sglt2","status":"publish","type":"eb_course","link":"https:\/\/www.mdbriefcase.com\/fr\/courses\/maladie-renale-en-presence-de-diabete-de-type-2-optimiser-la-protection-renale-a-laide-des-inhibiteurs-du-sglt2\/","title":{"rendered":"Maladie r\u00e9nale en pr\u00e9sence de diab\u00e8te de type\u00a02\u00a0: optimiser la protection r\u00e9nale \u00e0 l\u2019aide des inhibiteurs du SGLT2"},"content":{"rendered":"<p>Ralentir l\u2019apparition et la progression de la maladie r\u00e9nale chronique (MRC) demeure un besoin clinique non satisfait chez les patients atteints de diab\u00e8te de type 2. Ce programme aide les pharmaciens \u00e0 assurer la mise \u00e0 jour de leurs connaissances sur les options pharmacologiques qui ont d\u00e9montr\u00e9 des <strong>effets n\u00e9phroprotecteurs<\/strong> chez les patients atteints de diab\u00e8te de type 2 et d\u2019une MRC.<\/p>\n<p><strong>L\u2019efficacit\u00e9, l\u2019innocuit\u00e9<\/strong> et <strong>la posologie<\/strong> de ces m\u00e9dicaments n\u00e9phroprotecteurs seront illustr\u00e9es au moyen d\u2019un apprentissage fond\u00e9 sur des cas, afin d\u2019accro\u00eetre la confiance des pharmaciens dans l\u2019identification des patients en milieu communautaire qui pourraient en b\u00e9n\u00e9ficier, et dans la recommandation de cette classe de m\u00e9dicaments.<\/p>","protected":false},"featured_media":442047,"comment_status":"open","ping_status":"closed","template":"","eb_course_cat":[],"class_list":["post-83077","eb_course","type-eb_course","status-publish","has-post-thumbnail","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Maladie r\u00e9nale en pr\u00e9sence de diab\u00e8te de type\u00a02\u00a0: optimiser la protection r\u00e9nale \u00e0 l\u2019aide des inhibiteurs du SGLT2 - MDBriefCase<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.mdbriefcase.com\/fr\/cours\/maladie-renale-en-presence-de-diabete-de-type-2-optimiser-la-protection-renale-a-laide-des-inhibiteurs-du-sglt2\/\" \/>\n<meta property=\"og:locale\" content=\"fr_CA\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Maladie r\u00e9nale en pr\u00e9sence de diab\u00e8te de type\u00a02\u00a0: optimiser la protection r\u00e9nale \u00e0 l\u2019aide des inhibiteurs du SGLT2 - MDBriefCase\" \/>\n<meta property=\"og:description\" content=\"Ralentir l\u2019apparition et la progression de la maladie r\u00e9nale chronique (MRC) demeure un besoin clinique non satisfait chez les patients atteints de diab\u00e8te de type 2. Ce programme aide les pharmaciens \u00e0 assurer la mise \u00e0 jour de leurs connaissances sur les options pharmacologiques qui ont d\u00e9montr\u00e9 des effets n\u00e9phroprotecteurs chez les patients atteints de [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.mdbriefcase.com\/fr\/cours\/maladie-renale-en-presence-de-diabete-de-type-2-optimiser-la-protection-renale-a-laide-des-inhibiteurs-du-sglt2\/\" \/>\n<meta property=\"og:site_name\" content=\"MDBriefCase\" \/>\n<meta property=\"article:modified_time\" content=\"2023-05-02T13:31:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.mdbriefcase.com\/wp-content\/uploads\/2020\/10\/GettyImages-650717506-LMS600-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"600\" \/>\n\t<meta property=\"og:image:height\" content=\"338\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.mdbriefcase.com\\\/courses\\\/maladie-renale-en-presence-de-diabete-de-type-2-optimiser-la-protection-renale-a-laide-des-inhibiteurs-du-sglt2\\\/\",\"url\":\"https:\\\/\\\/www.mdbriefcase.com\\\/courses\\\/maladie-renale-en-presence-de-diabete-de-type-2-optimiser-la-protection-renale-a-laide-des-inhibiteurs-du-sglt2\\\/\",\"name\":\"Maladie r\u00e9nale en pr\u00e9sence de diab\u00e8te de type\u00a02\u00a0: optimiser la protection r\u00e9nale \u00e0 l\u2019aide des inhibiteurs du SGLT2 - MDBriefCase\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.mdbriefcase.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.mdbriefcase.com\\\/courses\\\/maladie-renale-en-presence-de-diabete-de-type-2-optimiser-la-protection-renale-a-laide-des-inhibiteurs-du-sglt2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.mdbriefcase.com\\\/courses\\\/maladie-renale-en-presence-de-diabete-de-type-2-optimiser-la-protection-renale-a-laide-des-inhibiteurs-du-sglt2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.mdbriefcase.com\\\/wp-content\\\/uploads\\\/2020\\\/10\\\/GettyImages-650717506-LMS600-1.png\",\"datePublished\":\"2022-11-09T14:26:38+00:00\",\"dateModified\":\"2023-05-02T13:31:37+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.mdbriefcase.com\\\/courses\\\/maladie-renale-en-presence-de-diabete-de-type-2-optimiser-la-protection-renale-a-laide-des-inhibiteurs-du-sglt2\\\/#breadcrumb\"},\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.mdbriefcase.com\\\/courses\\\/maladie-renale-en-presence-de-diabete-de-type-2-optimiser-la-protection-renale-a-laide-des-inhibiteurs-du-sglt2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/www.mdbriefcase.com\\\/courses\\\/maladie-renale-en-presence-de-diabete-de-type-2-optimiser-la-protection-renale-a-laide-des-inhibiteurs-du-sglt2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.mdbriefcase.com\\\/wp-content\\\/uploads\\\/2020\\\/10\\\/GettyImages-650717506-LMS600-1.png\",\"contentUrl\":\"https:\\\/\\\/www.mdbriefcase.com\\\/wp-content\\\/uploads\\\/2020\\\/10\\\/GettyImages-650717506-LMS600-1.png\",\"width\":600,\"height\":338},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.mdbriefcase.com\\\/courses\\\/maladie-renale-en-presence-de-diabete-de-type-2-optimiser-la-protection-renale-a-laide-des-inhibiteurs-du-sglt2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.mdbriefcase.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Course\",\"item\":\"https:\\\/\\\/www.mdbriefcase.com\\\/courses\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Maladie r\u00e9nale en pr\u00e9sence de diab\u00e8te de type\u00a02\u00a0: optimiser la protection r\u00e9nale \u00e0 l\u2019aide des inhibiteurs du SGLT2\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.mdbriefcase.com\\\/#website\",\"url\":\"https:\\\/\\\/www.mdbriefcase.com\\\/\",\"name\":\"MDBriefCase\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.mdbriefcase.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.mdbriefcase.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.mdbriefcase.com\\\/#organization\",\"name\":\"MDBriefCase\",\"url\":\"https:\\\/\\\/www.mdbriefcase.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/www.mdbriefcase.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.mdbriefcase.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/logo.webp\",\"contentUrl\":\"https:\\\/\\\/www.mdbriefcase.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/logo.webp\",\"width\":190,\"height\":36,\"caption\":\"MDBriefCase\"},\"image\":{\"@id\":\"https:\\\/\\\/www.mdbriefcase.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Maladie r\u00e9nale en pr\u00e9sence de diab\u00e8te de type\u00a02\u00a0: optimiser la protection r\u00e9nale \u00e0 l\u2019aide des inhibiteurs du SGLT2 - MDBriefCase","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.mdbriefcase.com\/fr\/cours\/maladie-renale-en-presence-de-diabete-de-type-2-optimiser-la-protection-renale-a-laide-des-inhibiteurs-du-sglt2\/","og_locale":"fr_CA","og_type":"article","og_title":"Maladie r\u00e9nale en pr\u00e9sence de diab\u00e8te de type\u00a02\u00a0: optimiser la protection r\u00e9nale \u00e0 l\u2019aide des inhibiteurs du SGLT2 - MDBriefCase","og_description":"Ralentir l\u2019apparition et la progression de la maladie r\u00e9nale chronique (MRC) demeure un besoin clinique non satisfait chez les patients atteints de diab\u00e8te de type 2. Ce programme aide les pharmaciens \u00e0 assurer la mise \u00e0 jour de leurs connaissances sur les options pharmacologiques qui ont d\u00e9montr\u00e9 des effets n\u00e9phroprotecteurs chez les patients atteints de [&hellip;]","og_url":"https:\/\/www.mdbriefcase.com\/fr\/cours\/maladie-renale-en-presence-de-diabete-de-type-2-optimiser-la-protection-renale-a-laide-des-inhibiteurs-du-sglt2\/","og_site_name":"MDBriefCase","article_modified_time":"2023-05-02T13:31:37+00:00","og_image":[{"width":600,"height":338,"url":"https:\/\/www.mdbriefcase.com\/wp-content\/uploads\/2020\/10\/GettyImages-650717506-LMS600-1.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.mdbriefcase.com\/courses\/maladie-renale-en-presence-de-diabete-de-type-2-optimiser-la-protection-renale-a-laide-des-inhibiteurs-du-sglt2\/","url":"https:\/\/www.mdbriefcase.com\/courses\/maladie-renale-en-presence-de-diabete-de-type-2-optimiser-la-protection-renale-a-laide-des-inhibiteurs-du-sglt2\/","name":"Maladie r\u00e9nale en pr\u00e9sence de diab\u00e8te de type\u00a02\u00a0: optimiser la protection r\u00e9nale \u00e0 l\u2019aide des inhibiteurs du SGLT2 - MDBriefCase","isPartOf":{"@id":"https:\/\/www.mdbriefcase.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.mdbriefcase.com\/courses\/maladie-renale-en-presence-de-diabete-de-type-2-optimiser-la-protection-renale-a-laide-des-inhibiteurs-du-sglt2\/#primaryimage"},"image":{"@id":"https:\/\/www.mdbriefcase.com\/courses\/maladie-renale-en-presence-de-diabete-de-type-2-optimiser-la-protection-renale-a-laide-des-inhibiteurs-du-sglt2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.mdbriefcase.com\/wp-content\/uploads\/2020\/10\/GettyImages-650717506-LMS600-1.png","datePublished":"2022-11-09T14:26:38+00:00","dateModified":"2023-05-02T13:31:37+00:00","breadcrumb":{"@id":"https:\/\/www.mdbriefcase.com\/courses\/maladie-renale-en-presence-de-diabete-de-type-2-optimiser-la-protection-renale-a-laide-des-inhibiteurs-du-sglt2\/#breadcrumb"},"inLanguage":"fr-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.mdbriefcase.com\/courses\/maladie-renale-en-presence-de-diabete-de-type-2-optimiser-la-protection-renale-a-laide-des-inhibiteurs-du-sglt2\/"]}]},{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.mdbriefcase.com\/courses\/maladie-renale-en-presence-de-diabete-de-type-2-optimiser-la-protection-renale-a-laide-des-inhibiteurs-du-sglt2\/#primaryimage","url":"https:\/\/www.mdbriefcase.com\/wp-content\/uploads\/2020\/10\/GettyImages-650717506-LMS600-1.png","contentUrl":"https:\/\/www.mdbriefcase.com\/wp-content\/uploads\/2020\/10\/GettyImages-650717506-LMS600-1.png","width":600,"height":338},{"@type":"BreadcrumbList","@id":"https:\/\/www.mdbriefcase.com\/courses\/maladie-renale-en-presence-de-diabete-de-type-2-optimiser-la-protection-renale-a-laide-des-inhibiteurs-du-sglt2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.mdbriefcase.com\/"},{"@type":"ListItem","position":2,"name":"Course","item":"https:\/\/www.mdbriefcase.com\/courses\/"},{"@type":"ListItem","position":3,"name":"Maladie r\u00e9nale en pr\u00e9sence de diab\u00e8te de type\u00a02\u00a0: optimiser la protection r\u00e9nale \u00e0 l\u2019aide des inhibiteurs du SGLT2"}]},{"@type":"WebSite","@id":"https:\/\/www.mdbriefcase.com\/#website","url":"https:\/\/www.mdbriefcase.com\/","name":"MDBriefCase","description":"","publisher":{"@id":"https:\/\/www.mdbriefcase.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.mdbriefcase.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-CA"},{"@type":"Organization","@id":"https:\/\/www.mdbriefcase.com\/#organization","name":"MDBriefCase","url":"https:\/\/www.mdbriefcase.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.mdbriefcase.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.mdbriefcase.com\/wp-content\/uploads\/2024\/07\/logo.webp","contentUrl":"https:\/\/www.mdbriefcase.com\/wp-content\/uploads\/2024\/07\/logo.webp","width":190,"height":36,"caption":"MDBriefCase"},"image":{"@id":"https:\/\/www.mdbriefcase.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.mdbriefcase.com\/fr\/wp-json\/wp\/v2\/eb_course\/83077","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.mdbriefcase.com\/fr\/wp-json\/wp\/v2\/eb_course"}],"about":[{"href":"https:\/\/www.mdbriefcase.com\/fr\/wp-json\/wp\/v2\/types\/eb_course"}],"replies":[{"embeddable":true,"href":"https:\/\/www.mdbriefcase.com\/fr\/wp-json\/wp\/v2\/comments?post=83077"}],"version-history":[{"count":0,"href":"https:\/\/www.mdbriefcase.com\/fr\/wp-json\/wp\/v2\/eb_course\/83077\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.mdbriefcase.com\/fr\/wp-json\/wp\/v2\/media\/442047"}],"wp:attachment":[{"href":"https:\/\/www.mdbriefcase.com\/fr\/wp-json\/wp\/v2\/media?parent=83077"}],"wp:term":[{"taxonomy":"eb_course_cat","embeddable":true,"href":"https:\/\/www.mdbriefcase.com\/fr\/wp-json\/wp\/v2\/eb_course_cat?post=83077"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}